Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases | Annals of the Rheumatic Diseases

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Article info

Co-stimulatory molecules

Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases

Authors

R L Wilder PubMed articles Google scholar articles

Correspondence to:
Dr R L Wilder;
wilderr{at}medimmune.com

Citation

Wilder RL

Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases

Annals of the Rheumatic Diseases 2002;61:ii96-ii99.

Publication history

First published November 1, 2002.

Online issue publication

April 13, 2016

Copyright information

Copyright 2002 by Annals of the Rheumatic Diseases